Figure 7. Regenerative effect of encapsulated CD34⁺ cells and CD34⁺-derived ECs on diabetic wounds.

A) Wound closure (relatively to initial wound area) in diabetic mice treated by topical application of 1×10⁵ CD34⁺ cells and 0.35×10⁵ CD34⁺-derived ECs (A.1), CD34⁺ cells (A.2) or CD34⁺-derived ECs (A.3), encapsulated in fibrin gels. Control wounds received a saline solution (PBS) only. Results are average ± SEM, n = 6. * denotes statistical significance (P<0.05). B) Representative images of vWF immunostaining of wounds at day 3. Scale bar represents 50 µm. C) Quantification of wound capillary density (number of capillaries per mm²), based on the vWF immunostaining results, for 3 and 10 day-old wounds in the different experimental groups. Results are average ± SEM, n = 3. ** denotes statistical significance (P<0.001). D) Cytokine expression on mouse wound samples excised 3 days post-wounding, as determined by a Bio-Plex mouse cytokine assay. Wounds had been treated by topical application of CD34⁺ cells or CD34⁺ cells plus CD34⁺-derived ECs encapsulated in fibrin gels. Control wounds received fibrin gel alone. Results are average ± SD, n = 3.